Borosil Scientific Limited Receives Credit Rating Reaffirmation from CARE Ratings

1 min read     Updated on 11 Dec 2025, 10:46 AM
scanx
Reviewed by
Suketu GScanX News Team
Overview

CARE Ratings Limited has reaffirmed Borosil Scientific Limited's credit ratings with CARE A- (Stable) for long-term facilities and CARE A1 for short-term facilities. The company's long-term/short-term bank facilities were enhanced to ₹99.47 crores from ₹97.90 crores, while long-term facilities were reduced to ₹0.53 crores from ₹2.10 crores. This rating reaffirmation demonstrates continued confidence in the company's creditworthiness and financial stability.

26975783

*this image is generated using AI for illustrative purposes only.

Borosil Scientific Limited has announced that CARE Ratings Limited has reaffirmed the company's credit ratings, demonstrating continued confidence in its financial stability. The rating agency issued a press release on December 9, 2025, confirming the reaffirmation of ratings for the company's banking facilities.

Credit Rating Details

CARE Ratings has maintained its assessment of Borosil Scientific Limited's creditworthiness across different facility categories. The rating reaffirmation covers both long-term and short-term banking facilities, providing clarity on the company's credit profile.

Facilities/Instruments Amount (₹ in crores) Rating Rating Action
Long-term bank facilities 0.53 (Reduced from 2.10) CARE A-; Stable Reaffirmed
Long-term/Short-term bank facilities 99.47 (Enhanced from 97.90) CARE A-, Stable/CARE A1 Reaffirmed

Facility Amount Adjustments

The rating reaffirmation comes alongside notable changes in facility amounts. The long-term bank facilities have been reduced to ₹0.53 crores from the previous ₹2.10 crores. Conversely, the combined long-term and short-term bank facilities have been enhanced to ₹99.47 crores from ₹97.90 crores, representing an increase in the company's available banking facilities.

Rating Significance

The CARE A- rating with stable outlook for long-term facilities indicates adequate degree of safety regarding timely servicing of financial obligations. The CARE A1 rating for short-term facilities reflects strong degree of safety regarding timely payment of financial obligations. The stable outlook suggests that the rating is unlikely to change in the near term.

Regulatory Compliance

Borosil Scientific Limited received this information on December 10, 2025, at approximately 3:45 p.m. The company has disclosed this development in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The detailed credit rating rationale is available on CARE's website for stakeholders seeking comprehensive analysis of the rating decision.

Historical Stock Returns for BOROSCI

1 Day5 Days1 Month6 Months1 Year5 Years
+0.09%-3.73%+0.47%-20.77%-18.64%-28.40%

Borosil Scientific Bolsters Subsidiary with ₹116.82 Crore Investment via Rights Issue

1 min read     Updated on 27 Nov 2025, 01:11 PM
scanx
Reviewed by
Riya DScanX News Team
Overview

Borosil Scientific Limited has invested ₹116.82 Crore in its subsidiary, Goel Scientific Glass Works Limited, through a rights issue of 1,16,81,557 shares at ₹10 per share. This investment increases Borosil's shareholding in Goel to 99.37%. The funds will be used for capital expenses, operational costs, and general corporate purposes, aiming to enhance Goel's capabilities in manufacturing industrial glass process systems and laboratory glassware.

25774924

*this image is generated using AI for illustrative purposes only.

Borosil Scientific Limited has made a significant move to strengthen its subsidiary, Goel Scientific Glass Works Limited, through a substantial rights issue investment. This strategic decision underscores Borosil's commitment to expanding its presence in the scientific glassware sector.

Investment Details

Aspect Details
Investment Amount ₹116.82 Crore
Number of Shares 1,16,81,557
Share Price ₹10.00 per share
Post-Investment Shareholding 99.37%

Purpose of Investment

The infusion of capital is aimed at supporting Goel Scientific Glass Works Limited in several key areas:

  1. Meeting capital expenses
  2. Covering operational costs
  3. Addressing general corporate purposes

This investment is expected to enhance Goel's capabilities in manufacturing industrial glass process systems and laboratory glassware, potentially strengthening its market position.

Impact on Ownership

The rights issue has resulted in a significant increase in Borosil Scientific's ownership of Goel Scientific Glass Works. With the post-allotment shareholding rising to 99.37%, Borosil has effectively consolidated its control over the subsidiary.

Strategic Implications

This move by Borosil Scientific Limited reflects a strategic approach to:

  • Consolidate its position in the scientific glassware market
  • Enhance operational synergies between the parent company and its subsidiary
  • Potentially improve the overall financial performance of the group

The substantial investment indicates Borosil's confidence in Goel's growth potential and its importance to the parent company's long-term strategy in the scientific equipment sector.

As the scientific glassware industry continues to evolve, this investment could position Borosil Scientific to capitalize on emerging opportunities and strengthen its competitive edge in both domestic and international markets.

Investors and industry observers will likely be watching closely to see how this investment translates into tangible benefits for both Borosil Scientific and Goel Scientific Glass Works in the coming quarters.

Historical Stock Returns for BOROSCI

1 Day5 Days1 Month6 Months1 Year5 Years
+0.09%-3.73%+0.47%-20.77%-18.64%-28.40%

More News on BOROSCI

1 Year Returns:-18.64%